Merz Pharma GmbH & Co. KGaA
As of the edition of 20 October 2026, Merz Pharma GmbH & Co. KGaA runs 9 drugs, 7 of them marketed; it is on route A at 2 targets and on route B at 1 target.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Family history
The records place 2 company names in this family.
Drugs by status
| Status | Count |
|---|---|
| Marketed | 7 |
| Went quiet | 1 |
| Stopped | 1 |
| Total | 9 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Botulinum toxin type a | none listed | 2 |
| Levodopa | none listed | 4 |
| Memantine | none listed | 5 |
| Glycopyrronium | none listed | 10 |
| Incobotulinumtoxina | Ended 2022 (computed from the first US licence) | 1 |
| Dalfampridine | none listed | 0 |
| Naftifine | none listed | 0 |
A route B row is one company at one target.
Where it needs a new molecule
Route A at 2 targets, route B at 1 target.
All 3 rows on route A or B
In the product3 company-target rows on route A or B; 0 are not shown here, and no score is.
See all 3 targets where Merz Pharma GmbH & Co. KGaA needs a new molecule, with the facts behind eachRequest access. Nothing is shown until you do.
Where its trials are
- Nervous system: 8 trials led
- Ear, nose and throat: 5 trials led
- Eye: 4 trials led